SCHEMBL6077845

SCHEMBL6077845

COC(=O)c1ccc(CN(OC)C(=O)C=C2OC(C)(C)OC2=O)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 0.38
ALDH1A1 P00352 3/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
RAB9A P51151 3/20 0.37
TSHR P16473 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
FAAH O00519 1/20 0.36
CYP4A11 Q02928 2/20 0.36
CYP4F2 P78329 1/20 0.35
KDM4E B2RXH2 2/20 0.35
NPC1 O15118 2/20 0.35
GAA P10253 1/20 0.35
HPGD P15428 1/20 0.35
MAPK1 P28482 1/20 0.35
HSD17B10 Q99714 1/20 0.35
IDH1 O75874 1/20 0.35
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6077839 1.00 LOXL2 (0.38) LOXL2ALDH1A1L3MBTL1RAB9ATSHR
SCHEMBL6450808 0.90 TAS2R14 (0.37) ALDH1A1L3MBTL1RAB9AMAPTKDM4E
SCHEMBL6078546 0.89 SIRT2 (0.35) ALDH1A1L3MBTL1MAPT
SCHEMBL6449541 0.89 SIRT2 (0.35) ALDH1A1L3MBTL1MAPT
SCHEMBL6077367 0.89 ALDH1A1 (0.41) ALDH1A1L3MBTL1TSHRSMN1; SMN2LMNA
SCHEMBL6077370 0.89 ALDH1A1 (0.41) ALDH1A1L3MBTL1TSHRSMN1; SMN2LMNA
SCHEMBL6879189 0.87 NPSR1 (0.36) ALDH1A1L3MBTL1RAB9AMAPTNPSR1
SCHEMBL6077491 0.86 ALDH1A1 (0.44) ALDH1A1L3MBTL1SMN1; SMN2MAPTNPSR1
SCHEMBL6077514 0.86 ALDH1A1 (0.38) ALDH1A1TSHRSMN1; SMN2LMNAMAPT
SCHEMBL6877621 0.86 ALDH1A1 (0.44) ALDH1A1L3MBTL1SMN1; SMN2MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7109186-B2 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment BRISTOL-MYERS SQUIBB COMPANY (US) 2006-09-19 US disclosed
US-6777440-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-08-17 US disclosed
US-20040110804-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-06-10 US disclosed
US-20030176495-A1 HIV Integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2003-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110804-A1 HIV integrase inhibitors CDKN1A, SAMHD1, CTCF LOXL2 4464/4885ALDH1A1 563/4885L3MBTL1 2246/4885
US-20030176495-A1 HIV Integrase inhibitors MAPT, RIF1, HPRT1 LOXL2 4585/4885ALDH1A1 976/4885L3MBTL1 480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.